| __timestamp | Iovance Biotherapeutics, Inc. | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 11606000000 |
| Thursday, January 1, 2015 | 12390000 | 10313000000 |
| Friday, January 1, 2016 | 25602000 | 9762000000 |
| Sunday, January 1, 2017 | 21262000 | 9830000000 |
| Monday, January 1, 2018 | 28430000 | 10102000000 |
| Tuesday, January 1, 2019 | 40849000 | 10615000000 |
| Wednesday, January 1, 2020 | 60210000 | 8955000000 |
| Friday, January 1, 2021 | 83664000 | 9634000000 |
| Saturday, January 1, 2022 | 104097000 | 10042000000 |
| Sunday, January 1, 2023 | 106916000 | 10504000000 |
Data in motion
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Merck & Co., Inc. and Iovance Biotherapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Merck's SG&A expenses have shown a relatively stable trend, averaging around $10 billion annually. This consistency reflects Merck's robust operational strategies and its ability to maintain efficiency despite market fluctuations.
In contrast, Iovance Biotherapeutics, a smaller player, has seen its SG&A expenses grow significantly, from approximately $9 million in 2014 to over $100 million in 2023. This tenfold increase highlights Iovance's aggressive expansion and investment in growth. While Merck's expenses have decreased by about 10% over the period, Iovance's have surged by over 1000%, showcasing their divergent strategies in managing operational costs.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Merck & Co., Inc.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Novartis AG
Merck & Co., Inc. vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Merck & Co., Inc. vs Merus N.V. Trends and Insights
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Geron Corporation
Comparing SG&A Expenses: Merck & Co., Inc. vs Evotec SE Trends and Insights
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: Walgreens Boots Alliance, Inc. vs Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: ACADIA Pharmaceuticals Inc. vs Iovance Biotherapeutics, Inc.